AgingResearch.NewsJoin free

Group ii mglur agonist

Intervention

1 paper1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional and 1 more
  • Cells1

Outcomes

1

Intrinsic excitability

upin rats1

1 study

  1. Group ii mglur agonist increases intrinsic excitability in rats.

    “postsynaptic activation of group II mGluRs enhances the intrinsic excitability of CA3 pyramidal neurons, and an exacerbated response is observed in older adult rats.”

    Animalshippocampal area CA3

    Aging-related adaptations of metabotropic glutamate receptors within the CA3 region of the rat hippocampus

    Neurobiology of aging3 Sep 2025

Latest

Related